Compare American States Water Company (AWR) vs AstraZeneca plc (AZN) Price & Performance

American States Water (AWR) trades at $85.05, up 0.64% today, with a bullish technical signal from moving averages and strong profitability metrics including a 19.66% net income margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200 million ATM equity offering. The stock shows consistent dividend performance with a 71-year growth streak, though recent quarters saw mixed earnings results versus expectations.

Outlook remains stable with revenue growth to $679 million in 2026 and solid cash flow, but risks include regulatory pressures and interest rate sensitivity. Analysts are cautious with only 20% buy ratings. The stock offers defensive appeal but faces execution risks in a high-valuation environment.

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.